Table 1

Baseline characteristics of patients treated with ipilimumab–nivolumab (I–N) for melanoma brain metastases

First-line I–N (n=25)Second-line and third-line I–N (n=30)Total population (n=55)P value
Age, year
 Median64.054.00.0273, M-W U=245
 Range23–7729–7523–77
Sex, no. (%)
 Male18 (72.0)21 (70.0)39 (70.9)0.999
ECOG, no. (%)
 08 (32.0)17 (56.7)25 (45.4)0.043
 114 (56.0)13 (43.3)27 (49.1)
 23 (12.0)0 (0.0)3 (5.4)
Primary melanoma, no. (%)
 Cutaneous16 (64.0)20 (66.7)36 (65.4)0.071
 Unknown primary5 (20.0)10 (33.3)15 (27.3)
 Other4 (16.0)0 (0.0)4 (7.3)
Lactate dehydrogenase at commencement of I–N, no. (%)
 Normal12 (48.0)8 (26.7)20 (36.4)χ2(2)=2.696, p=0.260
 High8 (32.0)14 (46.7)23 (40.0)
 Missing5 (20.0)8 (26.7)13 (23.6)
Mutation, no. (%)
 BRAFV6002 (8.0)30 (100.0)32 (58.2)<0.0001
 Non-BRAFV60023 (92.0)0 (0.0)23 (41.8)
Brain metastases at commencement of systemic therapy, no. (%)
 Yes25 (100.0)17 (56.7)42 (68.3)<0.0001
Corticosteroids at I–N start, no. (%)
 Any dose1 (4.0)3 (10.0)4 (7.3)0.617
 >10 mg prednisolone equivalent0 (0.0)2 (6.7)2 (3.6)0.999
  • Metastasis stage was defined as per the American Joint Committee on Cancer staging system, eighth edition. In the first-line group, primary melanoma was categorized as ‘other’ included mucosal melanoma (n=2), conjunctival (n=1) and acral (n=1). ECOG denotes Eastern Cooperative Oncology Group performance status

  • M-W, Mann-Whitney.